Two New Prostate Cancer Therapies Further Treatment Options

Two New Prostate Cancer Therapies Further Treatment Options
shutterstock_86097949Treatment of metastatic castration resistant prostate cancer (mCRPC) has progressed throughout the years due to a number of advances in knowledge and understanding of the disease. Beginning with androgen deprivation therapy (ADT) as the standard of care due to the 1941 finding that prostate cancer regresses with androgen withdrawal, treatment has continually focused on androgen receptors as targets for fighting mCRPC. "Changing Paradigms in Management of mCRPC" highlights a shifting focus from ADT therapy by either surgical or medical castration to inhibit steroid biosynthesis. Castration is proven to be effective due to the resulting low levels of serum testosterone for some individuals, but for others who have mCRPC, prostate cancer death is common. Inhibiting steroid biosynthesis sidesteps the fact that some prostate cancer cells amplify androgen receptor genes and become more sensitive to the low levels of circulating testosterone. A common target for inhibiting steroid biosynthesis is CYP17, a cytochrome P450 enzyme that enables two reactions required for sex steroid synthesis. Ketoconazole, a no
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *